Stockscreener 앱 받기
508.34
1.55%
-8.00
시간 외 거래:
508.34
전일 마감가:
$516.34
열려 있는:
$516.34
하루 거래량:
2.42M
Relative Volume:
1.68
시가총액:
$128.84B
수익:
$12.34B
순이익/손실:
$4.34B
주가수익비율:
30.14
EPS:
16.8685
순현금흐름:
$3.71B
1주 성능:
-1.38%
1개월 성능:
-3.76%
6개월 성능:
+12.57%
1년 성능:
+31.32%
1일 변동 폭
$505.01
$518.10
1주일 범위
$505.01
$525.29
52주 변동 폭
$374.17
$560.25
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-03-10 | 재확인 | Oppenheimer | Outperform |
| 2026-02-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Vertex Pharmaceuticals Inc Share PriceVRTX, RNS News, Articles, Quotes, & Charts (NASDAQ:VRTX) - Proactive financial news
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis - TradingView
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis - Yahoo Finance
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Vertex Pharma stock gains analyst support as JPMorgan raises price target - ad-hoc-news.de
VRTX Reinstated by JP Morgan -- Price Target Raised to $560 - GuruFocus
Vertex trades higher after JPM gives bullish rating - TradingView
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher - FXEmpire
Executives On The Move: Vertex Expands Its Leadership Team Following Crinetics Acquisition - insights.citeline.com
Vertex Pharma stock heads into the open after a modest gain - ad-hoc-news.de
Vertex Pharma EVP Jasper van Grunsven files initial beneficial ownership statement - Bitget
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks - Yahoo Finance
Vertex Pharmaceuticals (VRTX) executive gets 8,682-share stock grant - Stock Titan
Vertex (NASDAQ: VRTX) executive listed as insider with no reported shares - Stock Titan
Frazier Life Sciences nets $1.1B in long-running biotech fund - Fierce Biotech
Vertex Pharma stock edges near 52-week high as pipeline expansion supports valuation - ad-hoc-news.de
Vertex at Wells Fargo healthcare conference: renal pipeline takes center stage - Investing.com
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex Pharma stock falls as market digests Crinetics deal and valuation risks - ad-hoc-news.de
Anti-kickback law at play, court tells Vertex as it schools HHS - BioWorld News
Where does Vertex Pharmaceuticals (NASDAQ:VRTX) fit within the Healthcare stocks conversation? - Kalkine Media
Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution - Seeking Alpha
Vertex Pharma stock heads into the open after a 3.1 percent drop - ad-hoc-news.de
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send? - TradingKey
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock - The Motley Fool
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals stock edges lower as market digests strong Q2 figures and insider selling - AD HOC NEWS
Vertex shares fall as investors digest Crinetics acquisition and related financing plans - Quiver Quantitative
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Could Nasdaq Focus Lift Attention on Vertex Pharmaceuticals (NASDAQ:VRTX)? - Kalkine Media
Vertex Pharmaceuticals stock steadies near a 52-week high - AD HOC NEWS
David Taylor sold $ VRTX on Aug. 26, 2026 - Quiver Quantitative
Why Vertex stock is sliding today - Wealth Awesome
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Titan with 4.29% Upside and Robust Buy Ratings - DirectorsTalk Interviews
Vertex Pharma stock slips as revenue and EPS stay in view - AD HOC NEWS
Vertex makes some big people moves, completes its largest acquisition - The Boston Globe
Vertex Fertility Aid Plan Would Violate Kickback Law - Law360
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout - Fierce Biotech
Is Vertex Pharmaceuticals (VRTX) Undervalued Following Casgevy’s FDA Label Expansion? - simplywall.st
Vertex Tops Citi’s Biotech Picks After Crinetics Deal Completion By Investing.com - Investing.com Canada
Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount drop - fiercebiotech.com
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex stock wins Overweight at Morgan Stanley (VRTX:NASDAQ) - Seeking Alpha
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks? - Barchart.com
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report? - Yahoo Finance
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
버텍스 파마슈티컬 주식 (VRTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. |
Jul 02 '26 |
Sale |
524.99 |
1,500 |
787,485 |
45,321 |
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
0.58%
자본화:
|
볼륨(24시간):